Last reviewed · How we verify
Hualan TIV
Hualan TIV is a trivalent inactivated influenza vaccine that stimulates the immune system to produce antibodies against three strains of influenza virus.
Hualan TIV is a trivalent inactivated influenza vaccine that stimulates the immune system to produce antibodies against three strains of influenza virus. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | Hualan TIV |
|---|---|
| Also known as | Hualan Trivalent Influenza Vaccine |
| Sponsor | Sanofi |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus particles representing three seasonal flu strains (typically two A subtypes and one B lineage). Upon administration, it triggers both humoral and cellular immune responses, leading to the production of neutralizing antibodies and memory B cells that protect against infection with matching or closely related circulating strains.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Fever
- Fatigue
Key clinical trials
- A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months (PHASE3)
- Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine (PHASE3)
- Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years (PHASE4)
- Clinical Trial of the Inactivated Influenza Vaccine (0.25ml Formulation for Pediatric Use) (PHASE3)
- Clinical Trial of Inactivated Influenza Vaccine (0.5ml Formulation) (PHASE3)
- Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine (PHASE4)
- Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hualan TIV CI brief — competitive landscape report
- Hualan TIV updates RSS · CI watch RSS
- Sanofi portfolio CI